Dibrompropamidine isetionate is an antiseptic. Ointment containing dibrompropamidine isetionate is used to treat minor eye or eyelid infections, such as conjunctivitis and blepharitis.

Broxyquinoline is an anti-infective agent. It exerts activity against fungi and protozoa. Broxyquinoline (Intestopan) has been used in the treatment of diarrhoeas of different aetiology. Broxyquinoline is able to promote neovascularization.

Nifurzide, a synthetic antimicrobial agent of the nitrofuran group. The MICs were excellent for Campylobacter spp. (97 strains); slightly higher for Shigella spp. (50 strains) and Aeromonas spp. (22 strains); and highest for Salmonella spp. (100 strains) and Yersinia enterocolitica. At low concentrations of nifurzide, the growth rate of the Escherichia coli cultures decreased, and elongated, nonseptate cells appeared. At high concentrations, complete growth inhibition occurred, accompanied by a rather strong bactericidal effect, but the appearance of the cells was normal; in particular, no bacteriolytic effect was observed. A very large number of antibiotic molecules were bound per bacterial cell. After cell disruption, similar amounts of nifurzide were found in the cytoplasm, cytoplasmic membranes, and cell wall, respectively. Nifurzide had no effect on a general infection, but significantly decreased the number of colony-forming germs in the digestive tract. It was rather insoluble in aqueous media, did not cross the intestinal barrier, and was not substantially metabolized in the intestine. The obnoxious side effects of other nitrofurans (induction of vomiting and inhibition of monoamine oxidase) were not observed with nifurzide, which makes it an interesting therapeutic agent against enteric infections.

Nifurpirinol, 6-hydroxymethyl-2-[2-(5-nitro-2-furyl)vinyl]pyridine, has been widely used as an antibacterial drug against diseases of fish. M. Shimizu and Y. Takase showed marked inhibitory activity against many species of bacteria, including several fish pathogens. They found minimum inhibitory concentrations (MIC's) of 0.1 to 0.3 ug of Nifurpirinol (P-7138) per ml of broth medium (ug/ml) for Vibrio anguilIarum, Aeromonas salmonicida, and Aeromonas liquefaciens. The first designation for this drug was "P-7138." Subsequently, "Furanace" was designated as the trade name, and "nifurpirinol" was selected as the generic name.

Alexidine dihydrochloride, an antibacterial compound, which is used during endodontic procedures. It is a dibiguanide ahent and is effective inhibitor of protein tyrosine phosphatases localized to mitochondrion 1 (PTPMT1). It was noted that PTPMT1 could serve as a pharmacological target in the treatment of type II diabetes. Alexidine dihydrochloride is also an apoptosis-promoting agent possessing the anticancer properties.

Aluminum lactate is effective for treatment of dentinal hypersensitivity that was confirmed in the experiments of daily home use of a dental rinse, containing this substance. Aluminum lactate also was studied on rodents. Experiments have revealed, that subchronic exposure of this substance could lead to the memory reduce. This effect can be achieved by reducing the protein expression of low-density lipoprotein receptor protein-1, influencing the transportation of amyloid-beta peptides (Aβ), and leading to the accumulation of Aβ.

Methaniazide (metaniazide) is the methanesulfonate derivative of isoniazid with antibacterial properties. It is used used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Nifurfoline is an imidazolidine-2,4-dione belonging to the family of nitrofurans. The spectrum of activity of the molecule is wide. Nifurfolina acts in fact on Escherichia coli , Proteus , Klebsiella , Enterobacter , staphylococci and enterococci . The antibacterial mechanism of action consists of inhibition of the Krebs cycle in terms of the formation of acetyl coenzyme A, citric acid and oxalacetic acid. This triple inhibition leads to a drastic reduction in the production of energy necessary for the multiplication or survival of bacteria. The drug can induce resistance, but very slowly. Nifurfolina is indicated in the treatment of urinary tract infections, acute or chronic, sustained by sensitive germs, even secondary to instrumental investigations (for example bladder catheterization ). It is also indicated in cystitis, pyelitis, cystopielites, nephritis and pyelonephritis, urethritis and prostatitis.

Morniflumate is a non-steroidal anti-inflammatory drug and represent as a beta-morpholinoethyl ester of niflumic acid, which is rapidly hydrolyzed in the plasma, releasing the free acidic form, the molecule responsible for the pharmacological effects. It was shown, that morniflumate was effective in the treatment of chronic recurring bronchitis and inhibited cyclooxygenase-1, 2 (COX-1, 2). Morniflumate has a 30-year history of clinical use, particularly for the treatment of pain associated with pediatric ear-nose-throat (ENT) infection. In addition, it appears to be a valid and well-tolerated alternative to other NSAIDs, or to antibiotics, for the treatment of pain and other symptoms of soft tissue inflammation.